|Type||Buy / Hold / Sell|
|Year End 31st Dec||Unit||2017||2018||2019||2020||2021||2022E||2023E||CAGR / Avg|
|Diluted Normalised EPS|
|Op. Cashflow ps|
|Free Cashflow ps|
|Diluted Weighted Average Shares||m|
|Book Value ps|
Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through the DIS segment, which provides diagnostic information services to a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers, accountable care organizations (ACOs) and direct contract entities (DCEs). It is also engaged in two business operations, Diagnostic Information Services, which develops and delivers diagnostic information services that provide insights to a range of customers, and the Diagnostic Solutions group includes its risk assessment services business, which offers solutions for insurers and its healthcare information technology businesses, which offers solutions for healthcare providers. The Company’s services primarily are provided under the Quest Diagnostics brand. The Company is also engaged in providing outreach laboratory services business.
- Stephen Rusckowski CHM (64)
- James Davis CEO (59)
- Mark Guinan CFO (60)
- Michael Prevoznik SVP (59)
- Catherine Doherty SVP (58)
- Carrie Manner SVP (46)
- Timothy Ring LED (64)
- Tracey Doi IND
- Vicky Gregg IND (66)
- Wright Lassiter IND (57)
- Timothy Main IND (63)
- Denise Morrison IND (67)
- Gary Pfeiffer IND (71)
- Helen Torley IND (58)
- Gail Wilensky IND (77)
Upcoming Events for DGX
Q4 2022 Quest Diagnostics Inc Earnings Release
Q1 2023 Quest Diagnostics Inc Earnings Release
Quest Diagnostics Inc Annual Shareholders Meeting
Q2 2023 Quest Diagnostics Inc Earnings Release
As of Today at 06:18 UTC, shares in Quest Diagnostics are trading at $145.63. This share price information is delayed by 15 minutes.
Shares in Quest Diagnostics last closed at $145.63 and the price had moved by +7.81% over the past 365 days. In terms of relative price strength the Quest Diagnostics share price has outperformed the S&P500 Index by +17.38% over the past year.
The overall consensus recommendation for Quest Diagnostics is Hold. You can view the full broker recommendation list by unlocking its StockReport.
The Quest Diagnostics dividend yield is 1.76% based on the trailing twelve month period.
Last year, Quest Diagnostics paid a total dividend of $2.56, and it currently has a trailing dividend yield of 1.76%.Looking ahead, the next dividend pay date is 2023-02-01.
We do not have data on when Quest Diagnostics is to next pay dividends. The historic dividend yield on Quest Diagnostics shares is currently 1.76%.
To buy shares in Quest Diagnostics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $145.63, shares in Quest Diagnostics had a market capitalisation of $16.59bn.
Here are the trading details for Quest Diagnostics:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: DGX
Based on an overall assessment of its quality, value and momentum Quest Diagnostics is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Quest Diagnostics is $151.20. That is 3.82% above the last closing price of $145.63.
Analysts covering Quest Diagnostics currently have a consensus Earnings Per Share (EPS) forecast of $9.85 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Quest Diagnostics. Over the past six months, its share price has outperformed the S&P500 Index by +7.89%.
As of the last closing price of $145.63, shares in Quest Diagnostics were trading +5.29% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Quest Diagnostics PE ratio based on its reported earnings over the past 12 months is 16.86. The shares last closed at $145.63.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Quest Diagnostics' management team is headed by:
- Stephen Rusckowski - CHM
- James Davis - CEO
- Mark Guinan - CFO
- Michael Prevoznik - SVP
- Catherine Doherty - SVP
- Carrie Manner - SVP
- Timothy Ring - LED
- Tracey Doi - IND
- Vicky Gregg - IND
- Wright Lassiter - IND
- Timothy Main - IND
- Denise Morrison - IND
- Gary Pfeiffer - IND
- Helen Torley - IND
- Gail Wilensky - IND